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All urologists have faced patients suﬀering a renal cancer asking for the occurrence of the disease in their oﬀspring and very often
the answer to this question has not been well founded from the scientiﬁc point of view, and only in few cases a familial segregation
tree is performed. The grate shift seen in the detection of small renal masses and renal cancer in the last decades will prompt us
to know the indications for familial studies, which and when are necessary, and probably to refer those patients with a suspected
familial syndrome to specialized oncological centers where the appropriate molecular and familial studies could be done. Use
of molecular genetic testing for early identiﬁcation of at-risk family members improves diagnostic certainty and would reduce
costly screening procedures in at-risk members who have not inherited disease-causing mutations. This review will focus on the
molecular bases of familial syndromes associated with small renal masses and the indications of familial studies in at-risk family
members.
Copyright © 2008 Jos´ e Antonio L´ opez-Guerrero et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Renal cell carcinoma (RCC) aﬀects approximately 150000
people worldwide each year, causing close to 78000 deaths
annually, and its incidence seems to be rising [1]. This
rising trend is partially due to the growing use of new and
improved noninvasive abdominal imaging modalities, such
asultrasonography,CT,andMRI[2,3].Inmorerecentyears,
48–66% of RCCs have been detected incidentally as small
renal masses in asymptomatic patients, whereas historically
most cases were diagnosed following investigations for ﬂank
pain or hematuria [4]. RCC is not a single entity, but rather
comprises the class of tumors of renal epithelial origin.
Broad histological and molecular studies have resulted in a
consensus classiﬁcation of diﬀerent RCC subtypes (Table 1)
[5].
Most cases of RCC are thought to be sporadic whereas
there has been estimated that hereditary RCC syndromes
are estimated at 1–4% but have major clinical and scientiﬁc
implications [6, 7]. First, the identiﬁcation of predisposing
gene oﬀers the possibility of genetic testing: surveillance of
mutation carriers results in early diagnosis and treatment.
Secondly, the involvement of the same genes is demonstrated
in a number of sporadic RCCs, providing insight into the
various mechanisms of renal tumorigenesis [8]. To date,
10 familial syndromes associated with one or more of the
various histological subtypes of RCC have been described,
all of them inherited with an autosomal dominant trait,
that means that carrier individuals of a mutant allele have a
50% chance of passing the mutant gene to the oﬀspring and
therefore the associated disorder (Table 2)[ 9]. The diverse
nature of these predisposing genes implicates diﬀerent
mechanisms and biological pathways in RCC tumorigenesis.
Hence, identiﬁcation of mutations responsible for these
syndromes in healthy carriers constitutes a challenge in the
clinical management of these individuals.
There are no generally accepted screening guidelines for
hereditary RCC syndromes; however, some recommenda-
tions can be made. A hereditary predisposition to renal
cancer should be suspected whenever an individual who
is diagnosed with renal cancer has a close relative also
diagnosed with the disease, and/or when an individual
presentswithmultifocalrenaltumorsorahistoryofprevious
renal tumor. Family history should be obtained and a
pedigree created, paying speciﬁc attention to relatives with a
known history of cancer. Whenever possible (when a gene-
causing disease is identiﬁable), a germline genetic testing
should be performed on the proband. In addition, and as2 Advances in Urology
Table 1: Classiﬁcation of renal epithelial tumors.
Histological type Frequency Cell of origin Behavior Gene involved Chromosomal abnormalities
Conventional
(clear-cell) renal-cell
carcinoma
75% Proximal renal tubule Malignant VHL, BHD
−3p, +5q, −Y, −8p, −9p, −14q;
t(3;5)(p;q)
Papillary renal-cell
carcinoma
10–15% Proximal renal tubule Malignant MET, FH, HRPT2
+7, +17, −Y, +12, +16, +20;
t(X;1)(p11.2;q21.2),
t(X;17)(p11.2;q25.3)
Chromophobe renal
carcinoma
5% Intercalated cell of
renal collecting duct
Rarely malignant BHD −1, −2, −6, −10, −13, −17, −21
Oncocytoma 5% Intercalated cell of
renal collecting duct
Benign BHD
−1, −Y; t(5;11)(q35;q13),
t(9;11)(p23;q13)
Collecting-duct
carcinoma
2% Renal collecting duct Aggressively malignant FH −1p32, −6p, −8p, −21q
BHD,B i r t - H o g g - D u b´ e (encoding folliculin); FH, fumarate hydratase; HRTP2, hyperparathyroidism 2; VHL, von Hippel-Lindau.
Table 2: Hereditary renal cell carcinoma (RCC) syndromes and histological subtypes.
Renal tumors Manifestation Disease Gene
Clear cell RCC
Bilateral and multiple Von Hippel-Lindau VHL, 3p25-26
Bilateral and multiple Chromosome 3 translocations Unknown, VHL?
Hereditary paraganglioma SDHB, 1p36
Angiomyolipomas Tuberous sclerosis TSC1,9 q 3 4
TSC2, 16q13
Papillary RCC Solid, bilateral and multiple (type 1) Hereditary papillary RCC MET,7 q 3 1
Unilateral solitary, aggressive (type 2) Hereditary leiomyomatosis FH, 1q42-43
Hamartomas, Wilm’s tumor Hyperparathyroidism-jaw tumor HRPT2, 1q25-32
Oncocytoma Familial papillary thyroid cancer ?, 1q21
Chromophobe RCC Oncocytic-chromophobe Birt-Hogg-Dub´ e BHD, 17p11.2
a general rule, molecular genetic testing of at-risk family
members is appropriate in order to identify the need for
continued, lifelong, clinical surveillance. Interpretation of
the result is most accurate when a disease-causing mutation
has been identiﬁed in an aﬀected family member. Those
who have a disease-causing mutation require lifelong regular
surveillance. Meanwhile, family members who have not
inherited the mutation and their oﬀspring have risks similar
to the general population [10].
In this case, and generally speaking within a genetic
testing context, the presence or absence of a mutation in a
predisposing gene or the type of mutation determines the
clinical actuation in cases of hereditary syndromes of cancer.
In this sense, and following the American College of Medical
Genetics (ACMG) recommendations, we can describe the
following situations [10]:
Situation1.
When the mutation is present:
(i) the pathogenic sequence alteration is reported in the
literature;
(ii) sequence alteration is predicted to be pathogenic but
not reported in the literature;
(iii) sequence variation of unknown clinical signiﬁcance;
(iv) sequence alteration is predicted to be benign but not
reported in the literature;
(v) a benign sequence alteration is reported in the
literature.
Situation2.
Possibilities if a sequence alteration is not detected:
(i) patient does not have a mutation in the tested gene
(e.g., a sequence alteration exists in another gene at
another locus);
(ii) patient has a sequence alteration that cannot be
detected by sequence analysis (e.g., a large deletion,
a splice site deletion);
(iii) patient has a sequence alteration in a region of
the gene (e.g., an intron or regulatory region) not
covered by the laboratory’s test.
Herein we review the four most frequent syndromes
(von Hippel-Lindau, Hereditary papillary RCC, Hereditary
leiomyomatosis RCC, and Birt-Hogg-Dub´ e), the molecular
biologyoftheassociatedgenes,andtheclinicalconsequences
of a genetic counseling.Jos´ e Antonio L´ opez-Guerrero et al. 3
Table 3: Hereditary patterns and risks of renal cell carcinoma (RCC) associated syndromes.
Syndrome Hereditary pattern Risk of developing an RCC of the aﬀected individuals
Von Hippel-Lindau Autosomal dominant 75%
Papillary RCC Autosomal dominant 20%
Leiomyomatosis RCC Autosomal dominant 10–16%
Birt-Hogg-Dub´ e Autosomal dominant 15–29%
2. VON HIPPEL-LINDAU (VHL) DISEASE
2.1. Clinicalmanifestationandmolecularbiology
VHL (OMIM: 193300) is the main cause of inherited
RCC [11]. This syndrome includes central nervous system
(CNS) and retinal hemangioblastomas, clear cell RCC and
renalcysts,pheochromocytomas,neuroendocrinepancreatic
tumors and pancreatic cysts, and endolymphatic sac tumors
[12]. VHL occurs at a prevalence of about 1/36000 and
VHL-associated tumors with relatively high penetrance (80–
90%) develop in the second to fourth decades of life. RCC
aﬀects up to 75% of patients by the age of 60 years. RCC is
predominantly multiple and bilateral and occurs at a mean
age of 39 years [11, 12]( Table 3).
Genetically, VHL is caused by germline mutations in the
VHL tumor suppressor gene located on 3p25-26 accompa-
nied by inactivation of the wild-type copy of the VHL gene
in a susceptible cell through loss of heterozygosity (LOH),
promoter hypermethylation, or somatic mutation [6].
VHL disease tumor suppressor protein (pVHL) has been
implicated in a variety of functions including transcriptional
regulation,posttranscriptionalgeneexpression,proteinfold-
ing, extracellular matrix formation, and ubiquitinylation
[13]. The role of pVHL in the regulation of hypoxia-
inducible genes through the targeted ubiquitinylation and
degradation of hypoxia-inducible factor-1α (HIF1α)h a s
been elucidated, leading to a model of how disruption of
the VHL gene results in RCC and the production of highly
vascularized tumors.
Under normoxic conditions, HIF1α is hydroxilated
(−OH) on two conserved praline residues by a member
of the EGLN family of prolyl hydroxylase enzymes. This
hydroxylation provides a substrate-recognition site for the
pVHL-E3 ubiquitin ligase complex, which contains elongins
C and B, cullin-2 (CUL2), and RBX1. Polyubiquitylation
of HIF1α by the VHL complex leads to its proteasomal
degradation by the 26S proteasome [6]( Figure 1).
However, under hypoxic conditions, HIF1α is not
hydroxylated, pVHL does not bind, and HIF1α subunits
accumulate. HIF1α forms heterodimers with HIF1β and
activates transcription of a variety of hypoxia-inducible
genes (i.e., VEGF, EPO, TGFα,P D G F β). Likewise, when
pVHL is absent or mutated, HIF1α subunits accumulate,
resulting in cell proliferation and the neovascularization of
tumors characteristic of VHL disease [13].
Mutations in the VHL gene either prevent its expression
(i.e., deletions, and frameshifts, nonsense mutations, splice
site mutations) or lead to the expression of an abnormal
protein (i.e., missense mutations), and interesting genotype-
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Figure 1: VHL complex interaction with HIFα under normal O2
levels. Its normal function leads to HIFα degradation (see text for
details).
phenotype correlations are emerging for VHL disease that
relate to the development of RCC [14]. A group of VHL
mutations termed type 1, comprising mostly deletions and
premature-termination mutations that cause total loss of
pVHL function, predispose to the entire spectrum of VHL-
syndrome except pheocromocytomas [15]. By contrast,
type 2 mutations, which are mostly missense changes
that reduce pVHL activity, predispose to the entire VHL
spectrum, including pheochromocytomas with or with-
out RCC, called type 2B and type 2A, respectively [6].
Several studies have revealed that type 1 and type 2B
mutations, which predispose to RCC, show complete loss
of HIF1α ubiquitylation and regulation, whereas type 2A
mutations result in an incomplete defect in HIF regulation
[16]. However, type 2A mutations have been shown to
disrupt binding of pVHL to microtubules and abrogate
the associated microtubule-stabilizing function of pVHL,4 Advances in Urology
implicating defective cytoskeleton organization in this VHL
phenotype [17]. A third VHL-syndrome subclass (type 2C)
predisposes almost exclusively to pheochromocytomas [9].
Type 2C mutations produce pVHL that regulates HIF but
is defective in ﬁbronectin assembly, indicating a possible
link between ﬁbronectin-matrix assembly and pheochro-
mocytoma development [17]. Another class of VHL point
mutations inactivates pVHL function by disrupting proper
protein folding mediated by chaperonin TriC/CCT [18].
More recently, two independent groups reported a reduced
risk for RCC in individuals with a complete deletion of the
VHL gene. This group of individuals would deﬁne a new
VHL phenotype characterized by a low risk for both RCC
and pheochromocytoma [19, 20].
2.2. Moleculargenetictesting
The molecular genetic testing of VHL is mainly performed
by sequence analysis of all three exons which detects point
mutations and small deletions or insertions and that repre-
sents the 72% of VHL mutations, and deletion analysis (by
means of Southern Blot, MLPA, quantitative PCR, etc.) for
detecting partial or complete gene deletions, which account
for approximately 28% of all VHL mutations [21, 22].
Over 300 diﬀerent VHL germline mutations have been
identiﬁed [6, 11]. The mutations occur in all three exons,
with only a handful of mutations found in four or more
families (i.e., delPhe76, Asn78Ser, Arg161X, Arg167Gln,
Arg167Trp, Leu178Pro). Codon 167 is a hot spot muta-
tion. A database of mutations in the VHL gene is main-
tained on the human gene mutation database website
http://www.hgmd.cf.ac.uk/ac/index.php.
Molecular genetic testing is indicated in all individuals
known to have or suspected of having VHL syndrome
[23]. Since the detection rate for VHL gene mutations
is nearly 100%, molecular testing may also be used to
evaluate individuals with a single VHL-associated tumor
and a negative family history of the disease. In addition,
for individuals with manifestations of VHL syndrome who
do not meet strict diagnostic criteria and who do not have
a detectable VHL germline mutation, somatic mosaicism
for a de novo VHL disease-causing mutation should be
considered. In some instances, molecular genetic testing of
the oﬀspring of such individuals reveals a VHL mutation
[24].
The level of mutation detection obtained by molecular
genetictestingoftheVHLmakesitpossibletoeﬀectivelyrule
out VHL syndrome with a high degree of certainty in indi-
viduals with isolated hemangioblastoma, retinal angioma, or
c l e a rc e l lR C C ,w h oh a v en od e t e c t a b l eVHL disease-causing
germline mutation; somatic mosaicism for a VHL gene
mutation still needs to be considered in such individuals. A
younger individual, especially one with multiple lesions, is
more likely to have a germline VHL mutation than an older
individual with a single lesion [25].
Since pheochromocytoma is part of the VHL syndrome
spectrum and may occur as the exclusive manifestation of
VHL syndrome (type 2C), individuals with a family history
of these tumors, or those in whom the disease is bilateral
I
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Figure 2: Pedigree showing aﬀected members with VHL. Open
symbols,unaﬀectedsubjects;solidsymbols,aﬀectedsubjects;symbols
with slashes, deceased members; and arrow, proband.
or multifocal, should be oﬀered molecular genetic testing
for VHL germline mutations [26]. Germline VHL mutations
are rare in simplex cases of unilateral pheochromocytoma
(i.e., an aﬀected individual with no family history of VHL
syndrome), unless the individual is younger than age 20
years. Exceptions are those individuals with a family history
that is more consistent with familial paragangliomas of the
head and neck, which are caused by mutations in various
subunitsofthegeneencodingsuccinicdehydrogenase(SDH)
[27, 28], or those individuals who have features of other
heritable diseases associated with pheochromocytoma such
as multiple endocrine neoplasia type 2A or 2B or neuroﬁ-
bromatosis type 1 [25].
Use of molecular genetic testing for early identiﬁcation
of at-risk family members improves diagnostic certainty
and reduces the need for costly screening procedures in
those at-risk family members who have not inherited the
disease-causing mutation [29]. In addition, the American
Society of Clinical Oncologists (ASCO) identiﬁes VHL
syndrome as a Group 1 disorder, that is, a hereditary
syndrome for which genetic testing is considered part of the
standardmanagementforat-risk familymembers[30].Early
recognition of manifestations of VHL syndrome may allow
for timely intervention and improved outcome; thus, clinical
surveillance of asymptomatic at-risk individuals, including
children, for early manifestations of VHL syndrome is
appropriate.
2.3. Geneticcounseling
Genetic counseling is the process of providing individuals
and families with information on the nature, inheritance,
and implications of genetic disorders to help them make
informed medical and personal decisions.
As mentioned above, VHL syndrome is inherited in an
autosomal dominant manner, and we call proband (or index
case) to the aﬀected individual through whom a family with
a genetic disorder is ascertained. It has been reported that
about 80% of individuals diagnosed with VHL syndrome
have an aﬀected parent whereas de novo mutations of the
VHL gene are estimated to occur in about 20% of probands.
RecommendationsfortheevaluationofparentsofaprobandJos´ e Antonio L´ opez-Guerrero et al. 5
with an apparent de novo mutation include molecular
genetic testing if the VHL disease-causing mutation in the
proband is known. If the disease-causing VHL mutation in
the proband is not known, ophthalmologic screening and
abdominal ultrasound evaluation, at a minimum, should be
oﬀered to both parents [31].
In the case of the sibs of a proband, the risk of VHL
syndrome to sibs depends upon the genetic status of the
parents: if a parent of a proband is clinically aﬀected or has
a disease-causing VHL mutation, the sibs of the proband
are at 50% risk of inheriting the altered gene; and if neither
parent has the disease-causing VHL mutation identiﬁed in
the proband, the sibs have a small risk of VHL syndrome
because of the possibility of germline mosaicism in one
parent (at present the incidence of mosaicism is not known)
[24].
Each oﬀspring of an aﬀected individual has a 50% risk
of inheriting the mutant VHL gene; but the degree of
clinical severity is not predictable (Figure 2), whereas the
risk to other family members depends upon their biological
relationship to the aﬀected family member and can be
determined by pedigree analysis and/or molecular genetic
testing.
Molecular genetic testing of at-risk family members is
appropriate in order to determine the need for continued
clinical surveillance. Interpretation of molecular genetic test
results is most accurate when a disease-causing germline
mutation has been identiﬁed in an aﬀected family member.
Thosewhohavethedisease-causingmutationrequireregular
surveillance, whereas family members who have not inher-
ited the disease-causing mutation and their oﬀspring need
have no future concern [31].
Because early detection of at-risk individuals aﬀects
medical management, testing of asymptomatic individuals
during childhood is beneﬁcial [30]. As ophthalmologic
screening for those at risk for VHL syndrome begins as early
as possible, certainly before age ﬁve years, molecular genetic
testing may be considered in young children. Molecular
genetic testing may be performed earlier if the results would
alter the medical management of the child.
The use of molecular genetic testing for determining
the genetic status of presumably at-risk relatives when a
family member with a clinical diagnosis of VHL syndrome
is not available for testing is less straightforward. Such
test results need to be interpreted with caution. A positive
test result signals the presence of a VHL disease-causing
mutation in the at-risk family member and indicates that
the same molecular genetic testing method can be used to
assess the genetic status of other at-risk family members.
However,anegativetestforaVHLgenemutationundersuch
circumstances suggests one of the following possibilities:
(i) the at-risk family member has not inherited a VHL
disease-causing mutation;
(ii) the familial VHL mutation may not be detectable by
the assays used; or
(iii) the diagnosis of VHL syndrome in the aﬀected family
member is questionable.
In this situation, the presumably at-risk family member
has a small, but ﬁnite, residual risk of having inherited
a disease-causing allele (i.e., VHL syndrome or other
hereditary disorder). In counseling such individuals, careful
consideration should be given to the strength of the clinical
diagnosis of VHL syndrome in the aﬀected family member,
therelationshipoftheat-riskindividualtotheaﬀectedfamily
member, the perceived risk of an undetected VHL (or other)
gene mutation, and the potential need for some form of
continued clinical surveillance [31].
It is recommended that physicians ordering VHL molec-
ular genetic testing and individuals considering undergoing
testing understand the risks, beneﬁts, and limitations of the
testing prior to sending a sample to a laboratory. In fact,
in some countries the individuals must give and sign an
informed consent before the genetic analysis.
When neither parent of a proband with an autosomal
dominant condition has the disease-causing mutation or
clinical evidence of the disorder, it is likely that the proband
has a de novo mutation. However, possible nonmedical
explanations including alternate paternity or maternity (i.e.,
with assisted reproduction) or undisclosed adoption could
also be carefully explored.
3. HEREDITARY PAPILLARY RCC
3.1. Clinicalmanifestationandmolecularbiology
Hereditary papillary RCC (HPRCC) (OMIM 605074) is
characterized by the development of multifocal, bilateral
papillary type-1 RCCs (low-grade tumors with basophilic
cells and a favorable prognosis) occurring at a late age in
∼20% of gene carriers and a male/female ratio of 2:1 among
aﬀected members [6, 32]( Table 3). The pattern of inheri-
tance is consistent with autosomal dominant transmission
with reduced penetrance. Metastasis is less frequent, and
age-dependent penetrance in mutation carriers seems to be
reduced relative to penetrance in VHL syndrome [6].
HPRCC is mainly caused by activating germline muta-
tions in the tyrosine kinase domain of the MET proto-
oncogene. MET is located in 7q31 and codiﬁes a tyrosine
kinase receptor that is normally activated by hepatocyte
growth factor (HGF) [33]( Table 2). The MET–HGF sig-
nallingpathwayisimportantforcellproliferation,epithelial–
mesenchymal transitions, branching morphogenesis, diﬀer-
entiation and regulation of cell migration in many tissues.
Most of the germline mutations occur within the MET
activation loop or in the ATP-binding pocket and cause
ligand-independent MET activation (Figure 3)[ 34].
Tumors from patients with papillary RCC and germline
mutations of MET commonly show trisomy of chromosome
7 when analyzed by cytogenetic studies and comparative
genomic hybridization (CGH) providing the second activat-
ing event in the renal cells [9].
3.2. Moleculargenetictesting
The molecular genetic testing of MET is mainly performed
by sequence analysis of exons 16 to 19. All reported6 Advances in Urology
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Figure 3: Activating mutations in MET in HPRCC. (a) In normal cells, hepatocyte growth factor (HGF) binds to MET receptor to induce
MET dimerization and release autoinhibition. This permits, through several phosphorilation steps, the activation of second-messenger
molecules (such as GRB2, GAB1, or PI3K) leading to morphogenic, motogenic, and mitogenic programmes. (b) Renal cells from patients
with HPRCC can harbour germline mutations in the tyrosine kinase domain of MET. These mutations release the autoinhibition by the
MET carboxyl terminus, allowing the transition of the receptor to the active kinase form in absence of ligand stimulation.
alterations consist in point mutations. Ten known mutations
are clustered in exons 16–19 of the tyrosine kinase domain
and all are missense mutations which change the amino
acid (V1110I, H1112R, H1112Y, M1149T, V1206L, V1238I,
D1246N, Y1248C, Y1248D, M1268T). Mutations at four
codons (V1110, D1246, Y1248, M1268) are homologous
to sites of disease-associated activating mutations in other
RTKs (RET, c-kit, c-erbB). Two unrelated North American
families have been identiﬁed with the H1112R mutation and
shared ﬂanking genotyping data, suggesting a founder eﬀect.
Other mutations with only weak transforming potential
(Y1248C, L1213V) confer anchorage-independent growth
and an invasive phenotype in transfected cells.
Molecular genetic testing for a germline MET mutation
is indicated in all individuals known to have or suspected of
having HPRCC.
3.3. Geneticcounseling
There are no speciﬁc screening guidelines for families
suspectedofhavingHPRCC.Individualsinthesefamiliesare
encouraged to talk with their doctor about screening options
for kidney cancer, including ultrasound, and CT scan. Some
clinicians suggest that individuals who have HPRCC, or
a family history that suggests HPRCC, should have yearly
screening beginning at age 30.
4. HEREDITARY LEIOMYOMATOSIS RCC
4.1. Clinicalmanifestationandmolecularbiology
Hereditary leiomyomatosis renal cell cancer (HLRCC)
(OMIM 605839) predisposes to multiple cutaneous andJos´ e Antonio L´ opez-Guerrero et al. 7
uterine leiomyomas and solitary papillary type 2 RCCs [6,
35]( Table 2).
The majority of individuals (76%) present with a single
or multiple cutaneous leiomyoma. These lesions appear as
skin-colored to light brown papules or nodules distributed
over the trunk and extremities, and occasionally on the
face. Forty percent of individuals with HLRCC have mild
cutaneous manifestations with ﬁve or fewer lesions [36].
Histologically, proliferation of interlacing bundles of smooth
muscle ﬁbers with centrally located long blunt-edged nuclei
is observed.
Practically all females with HLRCC develop uterine
leiomyomas [36–38]. However, whether all women with
HLRCC have a higher risk of developing uterine leiomyosar-
comas is unclear. In the original description of HLRCC, it
was reported that 15% of women with uterine leiomyomas
also had uterine leiomyosarcoma [39].
Most renal tumors are unilateral and solitary. Approxi-
mately 10%–16% of individuals with HLRCC who present
withmultiple cutaneous leiomyomas hadrenal tumors atthe
timethatrenalimagingwasperformed[37,38].Mosttumors
are classiﬁed as “type 2” papillary renal cancer, which display
distinct papillary architecture and characteristic histopathol-
ogy (high-grade tumors with large eosinophilic cells, an
aggressive course, and a bad prognosis) [38]( Table 3). The
median age at detection of renal tumors is 44 years, and, in
contrast to other hereditary renal cancer syndromes, renal
cancers associated with HLRCC are aggressive [38].
The disease is caused by germline mutations in the
tumor suppressor gene FH located in 1q42-43 that encodes
the mitochondrial Krebs cycle enzyme fumarate hydratase
(EC 4.2.1.2.) [35]. FH consists of ten exons encompassing
22.15kb of DNA and is highly conserved across species. The
active form of the enzyme is a homotetramer and catalyzes
the conversion of fumarate to L-malate. In mammals, there
are two fumarase isoforms (mitochondrial and cytosolic)
that are synthesized from the same mRNA. After initial syn-
thesis, the FH proteins are partially imported and processed
at the mitochondrial outer membrane [6].
Activity of FH enzyme can be measured in cultured skin
ﬁbroblasts or lymphoblastoid cells to conﬁrm the diagnosis.
Reduced activity (≤60%) of FH enzyme was found in all
aﬀected individuals with the diagnosis of HLRCC [40, 41].
The overall risk for renal tumor development is unclear
and the mechanism of FH-mutation-driven tumorigenesis
remains unknown so far [6]. It is plausible that intracellular
fumarate accumulation as a result of FH inactivation causes
decreased HIF degradation and overexpression of genes
more downstream in the HIF pathway [42].
4.2. Moleculargenetictesting
FH is the only gene known to be associated with HLRCC.
Between 80% and 100% of individuals with HLRCC have
identiﬁable sequence variants in FH [36–38]. The spec-
trum of mutations includes missense, insertion/deletion,
and nonsense mutations that are predicted to truncate the
protein, or substitute or delete highly conserved aminoacids,
along with several whole-gene deletion. About 40 diﬀerent
FH mutations have been identiﬁed and are distributed
throughout the entire gene without genotype-phenotype
correlation [40]. Several of the mutations occur in many
families, which could reﬂect a founder eﬀect; notably, the
Arg190His mutation, which is the most frequent mutation
(33%) in a North American family study, and the Arg58X
and Asn64Thr mutations in studies by the European-based
Multiple Leiomyoma Consortium [6].
Molecular genetic testing for a germline FH mutation is
indicated in all individuals known to have or suspected of
having HLRCC, including individuals with the following:
(i) multiple cutaneous leiomyomas (with at least one
histologically-conﬁrmed leiomyoma) without a fam-
ily history of HLRCC;
(ii) a single cutaneous leiomyoma with family history of
HLRCC;
(iii) one or more tubulo-papillary, collecting-duct, or
papillarytype2renaltumorswithorwithoutafamily
history of HLRCC.
Measurement of FH enzyme activity can be useful in the
diagnosis of HLRCC in cases with atypical presentation and
undetectable FH mutations [40, 41].
No correlation is observed between FH mutations and
the occurrence of cutaneous lesions, uterine ﬁbroids, or
renal cancer of HLRCC [36]. To date, six women with a
germline mutation in FH have been reported with uterine
leiomyosarcoma[43,44].ItseemsthatFH mutation-positive
families are in general not highly predisposed to uterine
cancer, but a few individuals and families seem to be at high
risk.
4.3. Geneticcounseling
HLRCC is inherited in an autosomal dominant manner.
Some individuals diagnosed with HLRCC have an aﬀected
parent and some have HLRCC as the result of a de novo
gene mutation. In this case, the proportion of cases caused
by de novo mutations is unknown as subtle manifestation
in parents has not been evaluated and genetic testing data
are insuﬃcient. Recommendations for evaluation of parents
of a proband with a suspected de novo mutation include
molecular genetic testing if the FH disease-causing mutation
in the proband has been identiﬁed. However, it is important
to note that although some individuals diagnosed with
HLRCC have an aﬀected parent, the family history may
appear to be negative because of failure to recognize the
disorder in family members, early death of the parent before
the onset of symptoms, or late onset of the disease in the
aﬀected parent.
In the case of the siblings of a proband, the risk depends
upon the genetic status of the proband’s parents. If a parent
of a proband is clinically aﬀected or has a disease-causing
mutation, each sibling of the proband is at a 50% risk
of inheriting the mutation. If the disease-causing mutation
cannot be detected in the DNA of either parent, the risk to
siblingsislow,butgreaterthanthatofthegeneralpopulation
because the possibility of germline mosaicism exists [38].8 Advances in Urology
The risk to other family members depends upon the
status of the proband’s parents. If a parent is found to be
aﬀected or to have a disease-causing mutation, his or her
family members are at risk.
It is not possible to predict whether symptoms will
occur, or if they do, what the age of onset, severity, and
type of symptoms, or rate of disease progression will be in
individuals who have a disease-causing mutation.
When neither parent of a proband with an autosomal
dominant condition has the disease-causing mutation or
clinical evidence of the disorder, it is likely that the proband
has a de novo mutation. However, possible nonmedical
explanations including alternate paternity or undisclosed
adoption could also be explored.
ThereisnoconsensusonclinicalsurveillanceforHLRCC
individuals so far but the following provisional recommen-
dations have been accepted until a consensus conference is
conducted [31].
Individuals with the clinical diagnosis of HLRCC,
individuals with heterozygous mutations in FH without
clinicalmanifestations,andat-riskfamilymemberswhohave
not undergone molecular genetic testing should have the
following regular surveillance by physicians familiar with the
clinical manifestations of HLRCC.
(i) Skin.Fullskinexaminationisrecommendedannually
to every two years to assess the extent of disease and
toevaluateforchangessuggestiveofleiomyosarcoma.
(ii) Uterus. Annual gynecologic consultation is recom-
mended to assess severity of uterine ﬁbroids and to
evaluate for changes suggestive of leiomyosarcoma.
(iii) Kidneys. If both the initial (baseline) and the ﬁrst
annual follow-up abdominal CT scan with contrast
are normal, this evaluation should be repeated every
two years.
Any suspicious renal lesion (indeterminate lesion, ques-
tionable or complex cysts) at a previous examination should
be followed with a CT scan with and without contrast. PET-
CT may be added to identify metabolically active lesions
suggesting possible malignant growth. It must be taken into
consideration that ultrasound examination alone is never
suﬃcient.
Renaltumorsshouldbeevaluatedbyaurologiconcology
surgeon familiar with the renal cancer of HLRCC.
5. BIRT-HOGG-DUB´ E SYNDROME
5.1. Clinicalmanifestationandmolecularbiology
Birt-Hogg-Dub´ e (BHD) syndrome (OMIM 135150) is a
genodermatosis that predisposes individuals to benign cuta-
neous lesions of the face and neck, spontaneous recurrent
pneumothorax and/or lung cysts, and renal tumors [6, 7].
Approximately 15–29% of individuals with BHD syndrome
h a v er e n a lt u m o r s[ 45, 46]( Table 3). The renal tumors are
usually bilateral and multifocal. Tumor types include renal
oncocytoma, chromophobe RCC, oncocytic hybrid tumor,
and a minority of clear cell RCC [47]. The most common
tumors are a hybrid of oncocytoma and chromophobe his-
tologic cell types, so-called oncocytic hybrid tumor (67%),
chromophobe RCC (23%), and renal oncocytoma (3%).
Only renal oncocytoma is considered a benign tumor [48].
Other types of renal tumors reported in lower frequency
include clear cell RCC and papillary renal carcinoma. Most
renal tumors are slow-growing. Median age of diagnosis is
48 years with range from 31 to 71 years [46].
The disease is caused by germline mutations in the BHD
(FLCN) gene on chromosome 17p11.2 [49]. BHD encodes
folliculin, a new protein with unknown function but it is
highly expressed in a variety of tissues including skin and
skinappendages,type1pneumocytes,anddistalnephronsof
the kidney [50]. Recent studies suggest that folliculin might
be involved in energy and/or nutrient sensing through the
AMPK and mTOR signaling pathways [51].
BHD somatic mutations are very rare in sporadic RCC
but hypermethylations are encountered in ∼30% of all RCC
histological types [52]. Germline mutations in BHD,p l u s
somaticmutationsandlossofheterozygosityintumortissue,
suggest that loss of function of the folliculin protein is the
basis of tumor formation in BHD syndrome [53].
5.2. Moleculargenetictesting
BHD is the only gene known to be associated with BHD
syndrome.Variousmutationshavebeenidentiﬁedinfamilies
with BHD syndrome. All mutations predict protein trun-
cation. The most common mutation is cytosine insertion
or deletion, which occurs in a polycytosine tract in exon
11, suggesting the presence of a hypermutable hot spot
[46, 47]. Fifty-three percent of families with BHD syndrome
have been found to have an insertion or deletion in the
polycytosine tract in exon 11 (mutational hot spot) [46].
Sequence analysis of all coding exons (exon 4–14) increases
the mutation detection in probands to 84% [46].
Molecular genetic testing is indicated in all individuals
known to have or suspected of having BHD syndrome
including individuals with the following.
(1) Fiveormorefacialortruncalpapuleswithatleastone
histologically conﬁrmed ﬁbrofolliculoma [54]w i t h
or without family history of BHD.
(2) A family history of BHD syndrome with a single
ﬁbrofolliculoma or a single renal tumor or history of
spontaneous pneumothorax.
(3) Multiple and bilateral chromophobe, oncocytic,
and/or oncocytic hydrid renal tumors.
(4) A single oncocytic, chromophobe, or oncocytic-
hydrid tumor and a family history of renal cancer
with any of the above renal cell tumor types.
(5) A family history of autosomal dominant primary
spontaneous pneumothorax without a history of
chronic obstructive pulmonary disease.
Mutations in BHD were found in families with dom-
inantly inherited spontaneous pneumothorax. PulmonaryJos´ e Antonio L´ opez-Guerrero et al. 9
involvement appears to be the only manifestation; pene-
trance is 100% [55, 56].
Acquired mutations in BHD have been identiﬁed in spo-
radic clear cell renal cell carcinoma [52, 57] and colon cancer
[58,59]withoutotherassociatedtumorscharacteristicofthe
heritable disease.
No correlation is observed between type of BHD
mutation and pulmonary and cutaneous manifestations.
However,individualswhohaveadeletioninthepolycytosine
tract of exon 11 may have a lower risk of developing renal
cancers than individuals with other mutations [46].
5.3. Geneticcounseling
BHD syndrome is inherited in an autosomal dominant
manner. Some individuals with BHD syndrome have an
aﬀe c t e dp a r e n ta n ds o m eh a v eB H Ds y n d r o m ea sar e s u l t
of a de novo gene mutation. The proportion of cases caused
by de novo mutations is unknown as a suﬃcient number of
parents have not been evaluated for subtle manifestations,
nor are there suﬃcient data on clinically unaﬀected parents
who have been evaluated by molecular genetic testing.
Recommendationsfortheevaluationofparentsofaproband
withasuspecteddenovomutationincludemoleculargenetic
testing if the disease-causing mutation in the BHD gene in
the proband is identiﬁed. But, although some individuals
diagnosed with BHD syndrome have an aﬀected parent, the
family history may appear to be negative because of failure
to recognize the disorder in family members, early death of
the parent before the onset of symptoms, or late onset of the
disease in the aﬀected parent.
The risk to the siblings of the proband depends upon
the genetic status of the proband’s parents. If a parent of
a proband is clinically aﬀected or has a disease-causing
mutation, the sibs of the proband are at a 50% risk of
inheriting the mutation. If neither parent has the disease-
causing mutation identiﬁed in the proband, the risk to sibs is
low, but greater than that of the general population because
the possibility of germline mosaicism exists.
When neither parent of a proband with an autosomal
dominant condition has the disease-causing mutation or
clinical evidence of the disorder, it is likely that the proband
hasadenovomutation.However,otherpossiblenonmedical
explanations could also be explored.
There is no consensus on clinical surveillance; therefore,
these recommendations are provisional until a consensus
conference is conducted.
Individuals with known BHD syndrome, individuals
known to have disease-causing mutations in BHD without
clinical manifestation, and at-risk family members who
have not undergone genetic testing should have regular
monitoringbyphysiciansfamiliarwiththespectrumofBHD
syndrome. In particular, surveillance for and monitoring of
renal tumors include the following:
(i) if normal at baseline, abdominal/pelvic CT scan with
contrast every two years;
(ii) if any suspicious lesion (indeterminate lesion, ques-
tionable or complex cysts) at previous examination,
annualabdominal/pelvicCTscanwithcontrastalter-
nating every other year with MRI to reduce lifetime
exposure to radiation;
(iii) evaluation of renal tumors by a urologic surgeon;
(iv) monitoring of tumors less than three centimeters in
diameter by periodic imaging; they may not require
surgical intervention while this small.
6. FUTURE TRENDS
The identiﬁcation of genes responsible for inherited RCC
has resulted in a better understanding of renal tumorigenesis
including sporadic RCC and is paving the way for new
therapeutic approaches [6, 7]. For VHL, recent and ongoing
insights into the functions of the VHL gene, especially the
HIF-ubiquitylation pathway, provide an attractive molecular
basis for the development of speciﬁc inhibitors of HIF
and/or its downstream targets [13]. Preliminary studies with
the VEGF receptor inhibitor SU5416 showed that at least
a third of patients with advanced VHL disease improved
their clinical status giving promising expectations [60]. In
same directions, new protein kinase receptor inhibitors are
emerging [9]. In HPRCC, MET inhibitors gave encouraging
results in in vitro studies, but clinical trials have started very
recently and although data on the antitumor activity of the
anti-MET compounds are not yet available, these studies
haveshownthatMETinhibitionresultsinlow-gradetoxicity,
in agreement with the preclinical analyses performed in
animal models [61, 62].
Recent studies suggest that HIF overexpression is
involved in HLRCC tumorigenesis [42, 63]. Therefore,
future target therapies for HLRCC-associated tumors may
include, for example, anti-HIF therapies such as R59949
that regulate prolyl hydroxylase activity, thus preventing HIF
accumulation.
The study of families with increased rates of cancer
will continue to yield more insight into the factors that
increase cancer risk. Genetic predisposition in the form of
mutations and polymorphisms will increasingly be cata-
logued and DNA-level genetic proﬁling of high-risk families
and individuals will become commonplace. The increase
in availability of genetic testing and counseling for high-
risk families should prove both helpful and cost-eﬀective, as
genetically unaﬀected family members reassured regarding
their health status and removed from lifelong follow-up
screening programmes.
Finally, we also should keep in mind, although not
deeply discussed in this review, the psychological and ethical
implications of the genetic counseling [64–66], not only
from the strictly clinical point of view, but also regarding the
managementofpersonalgeneticinformationthatcouldhave
an impact on the individual and their relatives from certain
health insurance companies.
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